Page 12 - Diversity Impact Report - Atrium Health
P. 12
Un-sickling Cells
Atrium Health is at the forefront of treatment innovation and care for
Sickle Cell Disease (SCD), including new medications, enhanced pain
management and cutting edge curative therapies.
Modern Meds
“ Ifeyinwa Osunkwo, MD, MPH We participated in research that led to the FDA approval of a new SCD
Director, Comprehensive Sickle
pain medication, Endari™. The medication is only the second of its kind to
Cell Enterprise at Atrium Health
receive this approval in over 20 years. It has been shown to reduce painful
I am Atrium Health Proud because our complications of sickle cell by up to 30%.
healthcare organization continues to be in the
vanguard of providing the best care possible for Bypassing Pain
our patients with sickle cell disease.” Atrium Health has led the way in out-of-the box treatments, such as
buprenorphine/naloxone. Treatments like this make it possible to
mitigate the pain of SCD, while avoiding complications associated with
traditional opioids: tolerance and dependency.
Restoring Health
We are participating in an international study on the use of “half match”
donors— as compared to a full match previously required— to cure SCD.
This could provide access to a cure for everyone with the disease.
12 Diversity Impact Report
